Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy

Background: An objective method is needed for assessing facial fat changes in HIV-infected patients. Objective: To measure facial fat changes using three-dimensional laser scans (LS) and examine the relationship with clinically assessed lipoatrophy changes and dual-energy X-ray absorptiometry (DEXA)...

Full description

Bibliographic Details
Main Authors: Yong, Yang, Yap, Marline, Naing Oo Tha, Paton, Nicholas I
Format: Article
Language:English
English
Published: Taylor and Francis Ltd. 2008
Subjects:
Online Access:https://eprints.ums.edu.my/id/eprint/31646/1/Objective%20assessment%20of%20facial%20lipoatrophy%20changes%20in%20a%20cohort%20of%20HIV%20infected%20patients%20taking%20combination%20antiretroviral%20therapy.pdf
https://eprints.ums.edu.my/id/eprint/31646/2/Objective%20assessment%20of%20facial%20lipoatrophy%20changes%20in%20a%20cohort%20of%20HIV%20infected%20patients%20taking%20combination%20antiretroviral%20therapy_ABSTRACT.pdf
_version_ 1825714546408423424
author Yong, Yang
Yap, Marline
Naing Oo Tha
Paton, Nicholas I
author_facet Yong, Yang
Yap, Marline
Naing Oo Tha
Paton, Nicholas I
author_sort Yong, Yang
collection UMS
description Background: An objective method is needed for assessing facial fat changes in HIV-infected patients. Objective: To measure facial fat changes using three-dimensional laser scans (LS) and examine the relationship with clinically assessed lipoatrophy changes and dual-energy X-ray absorptiometry (DEXA) measured body composition changes in a cohort of patients taking combination antiretroviral therapy (ART). Method: Consecutive patients taking ART for at least 12 months were recruited from an outpatient clinic. Clinical lipoatrophy assessment, LS of the face, and whole-body DEXA were performed at baseline and repeated after 12 months. Cheek surface volume (CSV) change and cheek surface point displacement (CPD) change were calculated from the LS using a standardized technique. Results: Baseline and follow-up assessments were obtained in 146 patients. In the 102 patients with stable clinical lipoatrophy grade during follow-up, there was no CSV change (0.0 +/- 1.7 mL). In the 27 patients with clinical lipoatrophy progression, CSV decreased by 1.3 +/- 1.8 mL (p < .001 vs. stable patients); in the 17 patients with clinical facial lipoatrophy recovery, CSV increased by 1.0 +/- 1.7 mL (p = .092 vs. stable patients). CSV change was significantly related to limb fat change in the overall cohort (r = 0.32, p < .001). Multivariate regression analysis showed that stavudine use was a significant independent predictor of CSV (beta = -0.20, p = .038). Similar results were seen with calculation of CPD change. Conclusion: LS can detect facial lipoatrophy changes in a cohort of patients over time and can clearly detect the effects of individual drugs. This may be an objective and reliable method to assess facial fat change in future clinical trials.
first_indexed 2024-03-06T03:13:26Z
format Article
id ums.eprints-31646
institution Universiti Malaysia Sabah
language English
English
last_indexed 2024-03-06T03:13:26Z
publishDate 2008
publisher Taylor and Francis Ltd.
record_format dspace
spelling ums.eprints-316462022-02-25T01:23:25Z https://eprints.ums.edu.my/id/eprint/31646/ Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy Yong, Yang Yap, Marline Naing Oo Tha Paton, Nicholas I RC581-951 Specialties of internal medicine Background: An objective method is needed for assessing facial fat changes in HIV-infected patients. Objective: To measure facial fat changes using three-dimensional laser scans (LS) and examine the relationship with clinically assessed lipoatrophy changes and dual-energy X-ray absorptiometry (DEXA) measured body composition changes in a cohort of patients taking combination antiretroviral therapy (ART). Method: Consecutive patients taking ART for at least 12 months were recruited from an outpatient clinic. Clinical lipoatrophy assessment, LS of the face, and whole-body DEXA were performed at baseline and repeated after 12 months. Cheek surface volume (CSV) change and cheek surface point displacement (CPD) change were calculated from the LS using a standardized technique. Results: Baseline and follow-up assessments were obtained in 146 patients. In the 102 patients with stable clinical lipoatrophy grade during follow-up, there was no CSV change (0.0 +/- 1.7 mL). In the 27 patients with clinical lipoatrophy progression, CSV decreased by 1.3 +/- 1.8 mL (p < .001 vs. stable patients); in the 17 patients with clinical facial lipoatrophy recovery, CSV increased by 1.0 +/- 1.7 mL (p = .092 vs. stable patients). CSV change was significantly related to limb fat change in the overall cohort (r = 0.32, p < .001). Multivariate regression analysis showed that stavudine use was a significant independent predictor of CSV (beta = -0.20, p = .038). Similar results were seen with calculation of CPD change. Conclusion: LS can detect facial lipoatrophy changes in a cohort of patients over time and can clearly detect the effects of individual drugs. This may be an objective and reliable method to assess facial fat change in future clinical trials. Taylor and Francis Ltd. 2008 Article PeerReviewed text en https://eprints.ums.edu.my/id/eprint/31646/1/Objective%20assessment%20of%20facial%20lipoatrophy%20changes%20in%20a%20cohort%20of%20HIV%20infected%20patients%20taking%20combination%20antiretroviral%20therapy.pdf text en https://eprints.ums.edu.my/id/eprint/31646/2/Objective%20assessment%20of%20facial%20lipoatrophy%20changes%20in%20a%20cohort%20of%20HIV%20infected%20patients%20taking%20combination%20antiretroviral%20therapy_ABSTRACT.pdf Yong, Yang and Yap, Marline and Naing Oo Tha and Paton, Nicholas I (2008) Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy. HIV Clinical Trials, 9. pp. 399-406. ISSN 1528-4336 (P-ISSN) , 1945-5771 (E-ISSN) https://www.tandfonline.com/doi/pdf/10.1310/hct0906-399 https://doi.org/10.1310/hct0906-399 https://doi.org/10.1310/hct0906-399
spellingShingle RC581-951 Specialties of internal medicine
Yong, Yang
Yap, Marline
Naing Oo Tha
Paton, Nicholas I
Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy
title Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy
title_full Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy
title_fullStr Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy
title_full_unstemmed Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy
title_short Objective assessment of facial lipoatrophy changes in a cohort of HIV infected patients taking combination antiretroviral therapy
title_sort objective assessment of facial lipoatrophy changes in a cohort of hiv infected patients taking combination antiretroviral therapy
topic RC581-951 Specialties of internal medicine
url https://eprints.ums.edu.my/id/eprint/31646/1/Objective%20assessment%20of%20facial%20lipoatrophy%20changes%20in%20a%20cohort%20of%20HIV%20infected%20patients%20taking%20combination%20antiretroviral%20therapy.pdf
https://eprints.ums.edu.my/id/eprint/31646/2/Objective%20assessment%20of%20facial%20lipoatrophy%20changes%20in%20a%20cohort%20of%20HIV%20infected%20patients%20taking%20combination%20antiretroviral%20therapy_ABSTRACT.pdf
work_keys_str_mv AT yongyang objectiveassessmentoffaciallipoatrophychangesinacohortofhivinfectedpatientstakingcombinationantiretroviraltherapy
AT yapmarline objectiveassessmentoffaciallipoatrophychangesinacohortofhivinfectedpatientstakingcombinationantiretroviraltherapy
AT naingootha objectiveassessmentoffaciallipoatrophychangesinacohortofhivinfectedpatientstakingcombinationantiretroviraltherapy
AT patonnicholasi objectiveassessmentoffaciallipoatrophychangesinacohortofhivinfectedpatientstakingcombinationantiretroviraltherapy